AU2002337901B2 - Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use - Google Patents

Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use Download PDF

Info

Publication number
AU2002337901B2
AU2002337901B2 AU2002337901A AU2002337901A AU2002337901B2 AU 2002337901 B2 AU2002337901 B2 AU 2002337901B2 AU 2002337901 A AU2002337901 A AU 2002337901A AU 2002337901 A AU2002337901 A AU 2002337901A AU 2002337901 B2 AU2002337901 B2 AU 2002337901B2
Authority
AU
Australia
Prior art keywords
factor viii
polypeptide
sequence
seq
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002337901A
Other languages
English (en)
Other versions
AU2002337901A1 (en
Inventor
John S Lollar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Expression Therapeutics LLC
Original Assignee
Expression Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expression Therapeutics LLC filed Critical Expression Therapeutics LLC
Publication of AU2002337901A1 publication Critical patent/AU2002337901A1/en
Assigned to EXPRESSION THERAPEUTICS LLC reassignment EXPRESSION THERAPEUTICS LLC Request for Assignment Assignors: EMORY UNIVERSITY
Application granted granted Critical
Publication of AU2002337901B2 publication Critical patent/AU2002337901B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002337901A 2001-10-05 2002-10-07 Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use Ceased AU2002337901B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32738801P 2001-10-05 2001-10-05
US60/327,388 2001-10-05
PCT/US2002/033403 WO2003031598A2 (en) 2001-10-05 2002-10-07 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use

Publications (2)

Publication Number Publication Date
AU2002337901A1 AU2002337901A1 (en) 2003-07-03
AU2002337901B2 true AU2002337901B2 (en) 2008-01-17

Family

ID=23276347

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002337901A Ceased AU2002337901B2 (en) 2001-10-05 2002-10-07 Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use

Country Status (9)

Country Link
US (3) US7635763B2 (cg-RX-API-DMAC7.html)
EP (1) EP1572889B1 (cg-RX-API-DMAC7.html)
JP (2) JP4634036B2 (cg-RX-API-DMAC7.html)
AT (1) ATE417618T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002337901B2 (cg-RX-API-DMAC7.html)
CA (1) CA2461443C (cg-RX-API-DMAC7.html)
DE (1) DE60230456D1 (cg-RX-API-DMAC7.html)
ES (1) ES2319745T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003031598A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
DE60230456D1 (de) * 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
PL1750733T3 (pl) * 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US20110077202A1 (en) * 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
EP4169525A1 (en) * 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
HRP20210031T1 (hr) * 2013-06-24 2021-05-14 Weidong, Xiao Pripravci i metode mutantskog faktora viii
CN115094062A (zh) 2015-04-16 2022-09-23 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
KR102404550B1 (ko) 2015-11-13 2022-05-31 다케다 야쿠힌 고교 가부시키가이샤 A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
PE20181922A1 (es) 2016-04-15 2018-12-11 Univ Pennsylvania Terapia genica para tratar la hemofilia a
WO2019040743A1 (en) 2017-08-23 2019-02-28 Wake Forest University Health Sciences POST-NATAL TRANSPLANTATION OF CELLS EXPRESSING FACTOR VIII FOR THE TREATMENT OF HEMOPHILIA
US20200368286A1 (en) 2017-08-23 2020-11-26 Wake Forest University Health Sciences In utero transplantation of factor viii-expressing cells for treatment of hemophilia
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US11680109B2 (en) 2019-05-29 2023-06-20 Duke University Compositions and methods for detection and measurement of RNA modifications through targeted RNA editing
WO2022165390A1 (en) * 2021-01-29 2022-08-04 Expression Therapeutics, Llc Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071141A1 (en) * 1999-05-20 2000-11-30 Emory University Modified factor viii
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
DE60230456D1 (de) * 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO2000071141A1 (en) * 1999-05-20 2000-11-30 Emory University Modified factor viii

Also Published As

Publication number Publication date
JP4634036B2 (ja) 2011-02-16
DE60230456D1 (de) 2009-01-29
US20050118684A1 (en) 2005-06-02
US7635763B2 (en) 2009-12-22
JP2011015698A (ja) 2011-01-27
JP2005518783A (ja) 2005-06-30
ATE417618T1 (de) 2009-01-15
ES2319745T3 (es) 2009-05-12
CA2461443A1 (en) 2003-04-17
EP1572889A2 (en) 2005-09-14
EP1572889A4 (en) 2006-09-06
CA2461443C (en) 2011-07-12
US8188246B2 (en) 2012-05-29
WO2003031598A2 (en) 2003-04-17
EP1572889B1 (en) 2008-12-17
US8519111B2 (en) 2013-08-27
HK1080517A1 (en) 2006-04-28
JP5162635B2 (ja) 2013-03-13
US20110077203A1 (en) 2011-03-31
US20120270266A1 (en) 2012-10-25
WO2003031598A3 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
US8519111B2 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
AU2002337901A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
US7205278B2 (en) Stabilized proteins with engineered disulfide bonds
RU2285724C2 (ru) Рекомбинантная молекула днк, кодирующая модифицированный свиной фактор viii (pol 1212), экспрессирующие векторы, модифицированный свиной фактор viii, терапевтическая композиция, способы получения белка модифицированного свиного фактора viii (варианты) и линии клеток (варианты)
JP2005518783A5 (cg-RX-API-DMAC7.html)
ES2292255T3 (es) Polipeptido del factor viii con actividad de factor viii:c.
EP1424344A1 (en) Modified cDNA factor VIII and its derivates
AU2001292861A1 (en) Modified factor VIII
WO1995024427A1 (en) Hybrid human/animal factor viii
AU2002310438A1 (en) Stabilized proteins with engineered disulfide bonds
AU2002364509A1 (en) Factor viii c2 domain variants
AU606925B2 (en) A method for producing factor viii in high yield
US20230357360A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
EP2180009A1 (en) B-domain-deleted recombinant human Factor VIII.
HK1080517B (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
EP1454916A1 (en) Modified cDNA factor VIII and its derivatives

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EXPRESSION THERAPEUTICS LLC

Free format text: FORMER APPLICANT(S): EMORY UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired